CINCINNATI, March 29,
2022 /PRNewswire/ -- Meridian Bioscience, Inc.
(NASDAQ: VIVO), a leading global provider of diagnostic testing
solutions and life science raw materials, announced today the
launch of two new master mixes that detect DNA and RNA in crude
blood samples down to a single copy – enabling the earliest
detection of cancer using non-invasive liquid biopsy. These two
innovative mixes, Lyo-Ready™ Direct DNA qPCR Blood Mix and
Lyo-Ready™ Direct RNA/DNA qPCR Blood Mix, are designed for
applications that require ultra-sensitive detection, such as liquid
biopsy. This breakthrough technology is the first blood-specific,
inhibitor-tolerant, and lyophilizable chemistry that enables
extraction-free qPCR/RT-qPCR for liquid biopsy analysis at a
performance level on par with traditional qPCR from purified
nucleic acids.
![Meridian Bioscience, Inc. Logo (PRNewsfoto/Meridian Bioscience, Inc.) Meridian Bioscience, Inc. Logo (PRNewsfoto/Meridian Bioscience, Inc.)](https://mma.prnewswire.com/media/1655279/Meridian_Bioscience_Logo.jpg)
Liquid biopsy is a non-invasive alternative to tissue biopsy and
offers ultra-sensitive detection of tumor-associated DNA or RNA
from biofluids such as blood. Sample types like whole blood, serum,
plasma, and the anticoagulants used for specimen stabilization
contain PCR inhibitors that can significantly reduce detection
sensitivity and may cause false-negative results. Inhibitors are
usually removed by DNA/RNA extraction; however, that approach is
very inefficient and increases assay time, cost, and the risk of
contamination or error. Meridian's innovative Lyo-Ready™
Blood-Specific Master Mixes do not require extraction and are
proven to excel with crude blood and its derivatives without the
need to remove inhibitors. These groundbreaking mixes can help
improve patient outcomes by enabling early cancer detection by
delivering assay sensitivity down to one copy of DNA. Meridian's
new mixes are formulated with lyophilization excipients, making
them compatible with lyophilization to create room-temperature
stable molecular diagnostic assays. Not only does this allow
maximum sample input in the liquid biopsy analysis, but it also
eliminates the need for cold chain storage of the finished test
kit, limiting our customer's environmental impact.
Florent Chang-Pi-Hin, Ph.D., Vice
President, Global Research and Development, commented, "We are
excited to expand our sample-specific molecular range with the
market's first lyophilizable, and inhibitor-tolerant master mixes
designed for direct amplification of nucleic acids from liquid
biopsy. It is a truly disruptive technology that makes the early
detection of cancer biomarkers directly from liquid biopsy a
reality. We are proud of being the technology innovator enabling
efficient and more cost-effective diagnostic assay development to
help clinicians deliver the quickest, most accurate diagnosis for
patients."
Meridian is committed to supplying novel solutions to the
diagnostic industry to simplify and accelerate the development of
superior diagnostic assays. To learn more about Meridian's
groundbreaking mixes, visit
https://www.meridianbioscience.com/ambient-temperature-mixes or
contact Paul.Marr@meridianlifescience.com.
About Meridian Bioscience, Inc.
Meridian is a fully
integrated life science company that develops, manufactures,
markets, and distributes a broad range of innovative diagnostic
products. We are dedicated to developing and delivering better
solutions that give answers with speed, accuracy, and simplicity
that are redefining the possibilities of life from discovery to
diagnosis. Through discovery and development, we provide critical
life science raw materials used in immunological and molecular
tests for human, animal, plant, and environmental applications.
Through diagnosis, we provide diagnostic solutions in areas
including gastrointestinal and upper respiratory infections and
blood lead level testing. We build relationships and provide
solutions to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics
manufacturers, and biotech companies in more than 70 countries
worldwide.
Meridian's shares are traded on the NASDAQ Global Select Market,
symbol VIVO. Meridian's website address is
www.meridianbioscience.com.
Contact:
Charlie
Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/meridian-bioscience-launches-lyo-ready-qpcr-inhibitor-tolerant-blood-specific-master-mixes-for-dna--rna-direct-detection-301513098.html
SOURCE Meridian Bioscience, Inc.